Nanoshell implants use NIR (near-infrared) light to ablate cancer:
This article was originally published in Clinica
Executive Summary
Metal nanoshells inserted into tumours and irradiated with near-infrared (NIR) light could destroy cancers without damaging healthy tissue, an early US study has shown. The nanoshells may be able to absorb sufficient NIR light, from an extracorporeal source, to thermally ablate a tumour without harming normal tissue nearby, report study investigators, led by Jennifer West, of Rice University, in Houston, Texas. The findings appear in the Proceedings of the National Academy of Sciences (November 3).
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.